UrgoStart Contact
Also available with borders: click here
Also available as a foam : click here

Contact layer with TLC (Technology Lipido-Colloid) with NOSF (Nano-OligoSaccharide Factor) reducing the time to healing by 100 days (1)

 

Composition and properties

 
UrgoStart Contact

100 days logoUrgoStart® Contact is a contact layer with TLC-NOSF Technology (polyester mesh impregnated with hydrocolloid, petroleum jelly and healing accelerator NOSF particles).

Properties:

  • Contact layer with TLC–NOSF = Effective healing (8,11)
    • Improves patients' quality of life (11)
    • With all the benefits of TLC: pain-free dressing changes(2,3,4,5,6), moist wound-healing (2,7), good tolerance (8), stimulation of fibroblast proliferation (9,10)
    • Clinically proven in a Randomised Controlled Trial (8)

To find out more about TLC-NOSF please click here.

 

Indications

  • Non to low exuding leg ulcers, pressure ulcers, diabetic foot ulcers and recurring wounds
  • Can be combined with an absorbent layer
  • Can be used in cavity wounds
  • For best results use for recommended treatment duration of 12 weeks

Method of use

  • Add a secondary dressing
  • Secure with a retention bandage (K-Band, K-Lite)
  • Can be left in place for up to 7 days

Sizes available

 

Size Product CodePack Size
Product Code
PIP Code
5 x 7 cm 550276
10
550276 339-8971
10 x 10 cm 550278
10
550278 386-1390
15 x 20 cm 550277
10
550277 386-1382

Visit our website :

 

Clinical data available

 References:

(1) Münter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. Journal of Wound Care 2017; 26: WUWHS Suppl, S4–S15.

(2) Benbow M., Iossen G. A clinical evaluation of UrgoTul to treat acute and chronic wounds. Br J Nurs 2004: 13 (2): 105-109.

(3) Meaume S. et al. Optimizing wound care with a new lipido-colloid dressing (UrgoTul Duo) Br J Nurs 2007: 16 (6): S4-12.

(4) Smith J. et al. Evaluation of UrgoTul plus K-four compression for venous leg ulcers, Br J Nurs 2004: 13 (6): S20-28.

(5 )Fays S. et al. Leg ulcers and the UrgoCell Non-Adhesive wound dressing. Br J Nurs 2005: 14 (11):S15-20.

(6) UrgoCell® Start TLC/UrgoCell® TLC. Data on file, 2009. Urgo.

(7) Winter G.D. Formation of the scab and rate of epithelialisation of superficial wounds in the skin of the young domestic pig.
Nature 1962; 193: 293-294.

(8) Meaume S. et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-Oligo
Saccharide Factor wound dressing in the local management of venous leg ulcers. ; Wound Rep Reg. 2012 (July/ August) vol 20
issue 4, p 500-511

(9) Bernard F.X. et al. Stimulation of the proliferation of human dermal fibroblasts in vitro by a lipido-colloid dressing J Wound Care
2005; 14 (5): 215-220.

(10) UrgoStart®, UrgoStart® Contact. Data on file. 2011. Urgo.

(11) Schmutz JL. et al. Evaluation of the nano-oligo saccharide factor lipido-colloid matrix in the local management of venous leg ulcers: Results of a randomised controlled trial. International Wound Journal 2008; 5 (2):172-82.